Open AccessSwitching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]
Author(s) -
Martina Ranzenigo,
Nicola Gianotti,
Laura Galli,
Andrea Poli,
Andrea Mastrángelo,
Elena Bruzzesi,
Matteo Chiurlo,
Silvia Nozza,
Simona Bossolasco,
Vincenzo Spagnuolo,
Daniela Mancusi,
Roberta Termini,
Elisabetta Carini,
Adriano Lazzarin,
Antonella Castagna
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s394059
Subject(s) - darunavir , cobicistat , tenofovir alafenamide , emtricitabine , ritonavir , pharmacology , regimen , medicine , virology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load